Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03981094 · ClinicalTrials.gov registry record · Phase 1
A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT03981094 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 22 participants.
The verdict
NCT03981094, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The main objectives of this study are to characterize the PK of BMS-986278 after administration of a single dose of BMS-986278 alone or in combination with pirfenidone, as well as to characterize the PK of pirfenidone after administration of a single dose of pirfenidone alone or in combination with BMS-986278
Interventions
- DRUG Pirfenidone
- DRUG BMS-986278
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-05-10 |
| Est. Completion | 2019-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03981094
The ClinicalTrials.gov registry entry for NCT03981094 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pirfenidone is the first listed.
NCT03981094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03981094 about?
NCT03981094 is a clinical study titled "A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants". The main objectives of this study are to characterize the PK of BMS-986278 after administration of a single dose of BMS-986278 alone or in combination with pirfenidone, as well as to characterize the PK of pirfenidone after administration of a single dose of pirfenidone alone or in combination with ...
What is the current status of trial NCT03981094?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2019-05-10. Estimated completion is 2019-07-30.
What interventions are being tested in trial NCT03981094?
The interventions under investigation include: Pirfenidone (DRUG), BMS-986278 (DRUG).
Who is sponsoring clinical trial NCT03981094?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.